摘要
目的比较血液透析滤过(HDF)与常规血液透析(HD)对尿毒症患者β2-微球蛋白(β2-MG)清除的影响。方法查阅中国期刊全文数据库收录的自1992至2008年间发表的有关应用HDF与常规HD清除尿毒症患者β2-MG的临床试验资料;采用Review Manager5.0软件对纳入的试验结果进行荟萃分析。结果共纳入9项随机对照试验,共528例患者。HDF组、HD组两组间β2-MG的透析效应有统计学意义,合并治疗效应(95%可信区间)为:-9.86(-14.07,-5.66)。结论HDF比常规HD更能有效的清除尿毒症患者血清的β2-MG,从而降低透析相关性淀粉样变的发病危险。
Objective To compare the effect of clearing β2-microglobulin among Hemodiafiltration patients and convention hemodialysis patients. Methods We electronically searched clinical trials information from CNKI（1992 to 2008）. All clinical trials are about the clearance on β2-microglobttlin among hemodiafiltration （HDF） and/or convention hemodialysis （HD）. All results is analyzed according to the Cochrane Handbook for Systematic Reviews of Interventions. Results In total, nine randomized controlled trials met the inclusion criteria. Data from 528 patients were performed by Meta analysis. The clearence of β2-microglobulin between Hemodiafiltration and convention hemodialysis was significant difference, Conclusions Hemodiafiltration is more effective removal with serum β2-microglobulin than conventional hemodialysis, thereby reducing dialysis-related amyloidosis risk.
出处
《中国医药指南》
2009年第17期10-12,共3页
Guide of China Medicine
